Axsome Therapeutics, Inc. (AXSM)

Market Cap	4.40B
Revenue (ttm)	338.46M
Net Income (ttm)	-310.96M
Shares Out	48.46M
EPS (ttm)	-6.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	597,785
Open	88.82
Previous Close	89.74
Day's Range	87.69 - 93.12
52-Week Range	64.11 - 105.00
Beta	1.01
Analysts	Strong Buy
Price Target	125.93 (+38.8%)
Earnings Date	Feb 18, 2025

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2015
• Employees: 545
• Stock Exchange: NASDAQ
• Ticker Symbol: AXSM
• Website: https://www.axsome.com

Financial Performance

In 2023, Axsome Therapeutics's revenue was $270.60 million, an increase of 440.80% compared to the previous year's $50.04 million. Losses were -$239.24 million, 27.8% more than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is $125.93, which is an increase of 38.80% from the latest price.

Price Target

$125.93

(38.80% upside)

Analyst Consensus: Strong Buy